Editorial: Decernotinib: A Next-Generation Jakinib

The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention

(2015) John J. O'Shea et al.   Annual Review of Medicine

Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases

(2015) Luc J. Farmer et al.   JOURNAL OF MEDICINAL CHEMISTRY

A Randomized, Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral Selective JAK-3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis

(2015) Roy M. Fleischmann et al.   Arthritis & Rheumatology

VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis

(2015) Mark C. Genovese et al.   Arthritis & Rheumatology

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

(2014) Edward C Keystone et al.   ANNALS OF THE RHEUMATIC DISEASES

Advances in kinase inhibition

(2014) Massimo Gadina   CURRENT OPINION IN RHEUMATOLOGY

Tofacitinib versus Methotrexate in Rheumatoid Arthritis

(2014) Eun Bong Lee et al.   NEW ENGLAND JOURNAL OF MEDICINE

Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study*

(2013) Iain B McInnes et al.   ANNALS OF THE RHEUMATIC DISEASES

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

(2013) Gerd R Burmester et al.   LANCET

JAKs and STATs in Immunity, Immunodeficiency, and Cancer

(2013) John J. O'Shea et al.   NEW ENGLAND JOURNAL OF MEDICINE

Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate

(2008) G Wells et al.   ANNALS OF THE RHEUMATIC DISEASES